Phaseline

Companies › Agenus

Agenus: clinical trials, targets and expected readouts

2 active drug programs in 53 registered trials: 39 Phase 2, 12 Phase 1, 2 Phase 3; Oncology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Balstilimab
Programmed cell death protein 1 antagonist
PDCD1Phase 2Advanced Melanoma; Metastatic Colorectal Cancer; Advanced Cancer; Gastric Cancer …Sep 2027
Botensilimab
Anti-CTLA-4 monoclonal antibody
CTLA4Phase 2Advanced Melanoma; Metastatic Colorectal Cancer; Gastric Cancer; Colorectal Cancer Metastatic …Sep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05638698BalstilimabPhase 2Pancreas CancerOncologyDec 2024
NCT05529316BotensilimabPhase 2Advanced MelanomaOncologyApr 2026
NCT05529316BalstilimabPhase 2Advanced MelanomaOncologyApr 2026
NCT05318469BalstilimabPhase 1Anatomic Stage IV Breast Cancer AJCC v8OncologyOct 2026
NCT05672316BotensilimabPhase 1Advanced Colorectal AdenocarcinomaOncologyDec 2026
NCT05672316BalstilimabPhase 1Advanced Colorectal AdenocarcinomaOncologyDec 2026
NCT06300463BotensilimabPhase 2Colorectal Cancer MetastaticOncologyDec 2026
NCT06300463BalstilimabPhase 2Colorectal Cancer MetastaticOncologyDec 2026
NCT06336902BotensilimabPhase 1Metastatic Colorectal AdenocarcinomaOncologyJan 2027
NCT06336902BalstilimabPhase 1Metastatic Colorectal AdenocarcinomaOncologyJan 2027
NCT05632328BotensilimabPhase 2Advanced Pancreatic Ductal AdenocarcinomaOncologyApr 2027
NCT04028063BotensilimabPhase 2Metastatic Soft Tissue SarcomaOncologyApr 2027
NCT04028063BalstilimabPhase 2Metastatic Soft Tissue SarcomaOncologyApr 2027
NCT05845450BotensilimabPhase 2Colorectal CancerOncologyMay 2027
NCT07735624BotensilimabPhase 2Early Rectal CancerOncologyJun 2027
NCT07735624BalstilimabPhase 2Early Rectal CancerOncologyJun 2027
NCT05627635BotensilimabPhase 1Metastatic Colon AdenocarcinomaOncologyJun 2027
NCT05627635BalstilimabPhase 1Metastatic Colon AdenocarcinomaOncologyJun 2027
NCT06251973BotensilimabPhase 2Metastatic Esophageal CarcinomaOncologyAug 2027
NCT06251973BalstilimabPhase 2Metastatic Esophageal CarcinomaOncologyAug 2027
NCT05608044BotensilimabPhase 2Metastatic Colorectal CancerOncologySep 2027
NCT05608044BalstilimabPhase 2Metastatic Colorectal CancerOncologySep 2027
NCT04943848BalstilimabPhase 1Diffuse Intrinsic Pontine GliomaOncologySep 2027
NCT06780787BotensilimabPhase 2Rectal AdenocarcinomaOncologyNov 2027
NCT06780787BalstilimabPhase 2Rectal AdenocarcinomaOncologyNov 2027
NCT03860272BalstilimabPhase 1Advanced CancerOncologyDec 2027
NCT06843434BotensilimabPhase 2Microsatellite Stable Rectal CarcinomaOncologyFeb 2028
NCT06843434BalstilimabPhase 2Microsatellite Stable Rectal CarcinomaOncologyFeb 2028
NCT06346197BotensilimabPhase 3Gastric CancerOncologyMay 2028
NCT06346197BalstilimabPhase 3Gastric CancerOncologyMay 2028
NCT06268015BotensilimabPhase 2Colorectal CancerOncologyJul 2028
NCT06268015BalstilimabPhase 2Colorectal CancerOncologyJul 2028
NCT07550088BotensilimabPhase 2Colorectal Cancer MetastaticOncologySep 2028
NCT07550088BalstilimabPhase 2Colorectal Cancer MetastaticOncologySep 2028
NCT06782932BalstilimabPhase 1Pancreatic CancerOncologyDec 2028
NCT07595874BotensilimabPhase 2Advanced Colon AdenocarcinomaOncologyDec 2028
NCT07595874BalstilimabPhase 2Advanced Colon AdenocarcinomaOncologyDec 2028
NCT07516366BotensilimabPhase 2Clear Cell Renal Cell CarcinomaOncologyDec 2028
NCT07516366BalstilimabPhase 2Clear Cell Renal Cell CarcinomaOncologyDec 2028
NCT06279130BotensilimabPhase 2Resectable MMR-deficient Solid TumorsOncologyJan 2029
NCT06279130BalstilimabPhase 2Resectable MMR-deficient Solid TumorsOncologyJan 2029
NCT07551596BotensilimabPhase 2Colorectal AdenocarcinomaOncologyAug 2029
NCT07551596BalstilimabPhase 2Colorectal AdenocarcinomaOncologyAug 2029
NCT05891821BalstilimabPhase 2LymphomaOncologySep 2029
NCT06411691BotensilimabPhase 1Colorectal CancerOncologyNov 2029
NCT06411691BalstilimabPhase 1Colorectal CancerOncologyNov 2029
NCT06322108BalstilimabPhase 2Non-small Cell Lung CancerOncologyApr 2030
NCT06843551BotensilimabPhase 2Metastatic Pancreatic Ductal AdenocarcinomaOncologyAug 2030
NCT06843551BalstilimabPhase 2Metastatic Pancreatic Ductal AdenocarcinomaOncologyAug 2030
NCT07227636BotensilimabPhase 2Colorectal CancerOncologyNov 2030
NCT07227636BalstilimabPhase 2Colorectal CancerOncologyNov 2030
NCT05864534BotensilimabPhase 2Newly Diagnosed GlioblastomaOncologyJul 2031
NCT05864534BalstilimabPhase 2Newly Diagnosed GlioblastomaOncologyJul 2031

From the company's SEC filings

Cash and short-term investments of $87m on 2026-09-30; operating cash outflow about $117m a year; runway about 9 months at that burn, to Jun 2027; 5 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

CTLA4 (1) PDCD1 (1)

Companies with the same targets

Akeso AstraZeneca Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech Innovent Biopharmaceutical Technology (Hangzhou) Shenyang Sunshine Pharmaceutical OncoC4 Bristol-Myers Squibb Merck & Co. (MSD)

Companies built like this

CrystalGenomics Taizhou Hanzhong biomedical Coherus Oncology Summit Therapeutics Innate Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.